JHJ. Huober

J. Huober

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


J. Huober has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • A. Goldhirsch

    Department of Medicine, European Institute of Oncology, Milan, Italy

    1 shared publication
  • A. S. Coates

    International Breast Cancer Study Group and Australian New Zealand Breast Cancer Trials Group, University of Sydney, Sydney, Australia

    1 shared publication
  • B. Thürlimann

    Breast Center, Kantonsspital, St Gallen

    1 shared publication
  • C. Öhlschlegel

    Department of Pathology, Kantonsspital, St Gallen, Switzerland

    1 shared publication
  • G. Viale

    Division of Pathology and Laboratory Medicine, IBCSG Central Pathology Office, European Institute of Oncology, University of Milan, Milan, Italy

    1 shared publication
  • K. N. Price

    Frontier Science and Technology Research Foundation, Boston, USA

    1 shared publication

Latest Publications

  • Open Access

    Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials

    by J. Huober, S. Gelber, A. Goldhirsch, A. S. Coates, G. Viale, C. Öhlschlegel, K. N. Price, R. D. Gelber, M. M. Regan, B. Thürlimann

    To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12 409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13–0.78, P = 0.01). Medullary tumors have a favorable prognosis compared with invasive ductal tumors.